http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MY-145648-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c4180fc57a693864e2ce2dbfd64a9278
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-46
filingDate 2006-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91d431377692fde8963597d4380d49ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_941e09c8062c179e1d68c521a66266ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b0de0103c4d9697878b16915e7b5e63
publicationDate 2012-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MY-145648-A
titleOfInvention Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist
abstract THE PRESENT INVENTION IS DIRECTED TO THE DIHYDROGEN PHOSPHATE SALT OF 2-(3-{6-[2-(2,4-DICHLORO- PHENYL)-ETHYLAMINOL]-2-METHOXY-PYRIMIDIN-4-YL)-PHENYL)-2-METHYL-PROPIONIC ACID OF FORMULA (III), A PHARMACEUTICAL COMPOSITION COMPRISING A PHARMACEUTICALLY EFFECTIVE AMOUNT OF THE COMPOUND OF FORMULA (III), AND A PHARMACEUTICALLY ACCEPTABLE CARRIER; AND A METHOD OF TREATING A PATIENT SUFFERING FROM A PGD2-MEDIATED DISORDER INCLUDING, BUT NOT LIMITED TO, ALLERGIC DISEASE (SUCH AS ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, BRONCHIAL ASTHMA AND FOOD ALLERGY), SYSTERNIC MASTOCYTOSIS, DISORDERS ACCOMPANIED BY SYSTEMIC MAST CELL ACTIVATION, ANAPHYLAXIS SHOCK, BRONCHOCONSTRICTION, BRONCHITIS, URTICARIA, ECZEMA, DISEASES ACCOMPANIED BY ITCH (SUCH AS ATOPIC DERMATIFIS AND URTICARIA), DISEASES (SUCH AS CATARACT, RETINAL DETACHMENT INFLARRUNATION, INFECTION AND SLEEPING DISORDERS) WHICH IS GENERATED SECONDARILY AS A RESULT OF BEHAVIOR ACCOMPANIED BY ITCH (SUCH AS SCRATCHING AND BEATING), INFLAMMATION, CHRONIC OBSTRUCTIVE PULMONARY DISEASES, ISCHEMIC REPERFUSION INJURY, CEREBROVASCULAR ACCIDENT, CHRON IC RHEUMATOID ARTHRITIS, PLEURISY, ULCERATIVE COLITIS AND THE LIKE, BY ADMINISTERING TO SAID PATIENT A PHARMACEUTICALLY EFFECTIVE AMOUNT OF THE COMPOUND OF FORMULA (III).
priorityDate 2005-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1003
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411550721

Total number of triples: 35.